Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pulmodexane
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pulmodexane is a medication containing dextromethorphan hydrobromide, which functions as an antitussive (cough suppressant). It's primarily marketed in France and is used to treat dry, irritating coughs. Dextromethorphan is a non-opioid antitussive that works by affecting the signals in the brain that trigger the cough reflex. Its major metabolite, dextrorphan, binds with high affinity to σ-receptors to produce antitussive activity without exhibiting classic opiate effects that occur from binding to μ- and δ-receptors. At therapeutic doses, it doesn't cause respiratory depression or dependence.
- Brand names
- Pulmodexane
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)SIGMAR1 (Sigma non-opioid intracellular receptor 1)TMEM97 (Sigma-2 receptor complex (TMEM97/PGRMC1))σR (Sigma receptors)
Beyond the preview
Go deeper on Pulmodexane.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pulmodexane.